Literature DB >> 27325404

[Androprotect and prospects for fertility treatment].

S Kliesch1.   

Abstract

BACKGROUND: Fertility protection is essential for men undergoing potentially gonadotoxic treatment. It is usually offered to adolescents and men in reproductive age by semen cryopreservation. In case of azoospermia, testicular sperm cryopreservation is an additional option. In prepubertal boys no sperm cryopreservation is possible. A purely experimental option is cryopreservation of spermatogonial stem cells in immature testis tissue.
METHOD: Transplantation of either immature testis tissue or testicular stem cells or spermatogonia generated in vitro from stem cells are possible options for fertility preservation in boys.
OBJECTIVES: In this article, the rationale for cryopreservation of gonadal stem cells and the experimental methods for refertilization are summarized. The current research, national and international clinical and research activities and possible perspectives of further development of fertility preservation are explained.

Entities:  

Keywords:  Cryopreservation; Immature testis tissue; Spermatogenesis; Spermatogonial progenitor cells; Stem cell transplantation

Mesh:

Year:  2016        PMID: 27325404     DOI: 10.1007/s00120-016-0161-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  38 in total

1.  Progeny from sperm obtained after ectopic grafting of neonatal mouse testes.

Authors:  Stefan Schlatt; Ali Honaramooz; Michele Boiani; Hans R Schöler; Ina Dobrinski
Journal:  Biol Reprod       Date:  2003-02-05       Impact factor: 4.285

2.  Genetic and epigenetic stability of human spermatogonial stem cells during long-term culture.

Authors:  Bita Nickkholgh; S Canan Mizrak; Saskia K M van Daalen; Cindy M Korver; Hooman Sadri-Ardekani; Sjoerd Repping; Ans M M van Pelt
Journal:  Fertil Steril       Date:  2014-09-23       Impact factor: 7.329

3.  Array comparative genomic hybridization analysis does not show genetic alterations in spermatozoa and offspring generated after spermatogonial stem cell transplantation in the mouse.

Authors:  E Goossens; P de Vos; H Tournaye
Journal:  Hum Reprod       Date:  2010-05-19       Impact factor: 6.918

4.  Spermatogenesis following male germ-cell transplantation.

Authors:  R L Brinster; J W Zimmermann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

Review 5.  The use of epididymal sperm for the treatment of male infertility.

Authors:  S J Silber
Journal:  Baillieres Clin Obstet Gynaecol       Date:  1997-12

6.  Cryopreservation of sperm from adolescents and adults with malignancies.

Authors:  Axel Kamischke; Herbert Jürgens; Lothar Hertle; Wolfgang E Berdel; Eberhard Nieschlag
Journal:  J Androl       Date:  2004 Jul-Aug

7.  Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice.

Authors:  A Carmely; D Meirow; A Peretz; M Albeck; B Bartoov; B Sredni
Journal:  Hum Reprod       Date:  2009-02-24       Impact factor: 6.918

8.  Regeneration of spermatogenesis by grafting testicular tissue or injecting testicular cells into the testes of sterile mice: a comparative study.

Authors:  Dorien Van Saen; Ellen Goossens; Gert De Block; Herman Tournaye
Journal:  Fertil Steril       Date:  2008-04-18       Impact factor: 7.329

Review 9.  Testicular stem cells for fertility preservation: preclinical studies on male germ cell transplantation and testicular grafting.

Authors:  Stefan Schlatt; Jens Ehmcke; Kirsi Jahnukainen
Journal:  Pediatr Blood Cancer       Date:  2009-08       Impact factor: 3.167

10.  Cryopreservation of semen from adolescent patients with malignancies.

Authors:  S Kliesch; H M Behre; H Jürgens; E Nieschlag
Journal:  Med Pediatr Oncol       Date:  1996-01
View more
  2 in total

Review 1.  [Rational diagnosis and treatment of male infertility].

Authors:  S Kliesch
Journal:  Urologe A       Date:  2017-09       Impact factor: 0.639

Review 2.  [Andrology in oncological diseases].

Authors:  T Weberschock; S Grunewald; F Ochsendorf
Journal:  Hautarzt       Date:  2018-12       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.